Table IV.
SFRP2 expression and clinicopathological features in patients with Cushing's disease.
| Variable | SFRP2 expression [n (%)]
|
P-value | |
|---|---|---|---|
| High expression | Low expression | ||
| Sex | 1.000 | ||
| Male | 1 (4.35%) | 2 (8.70%) | |
| Female | 9 (39.13%) | 11 (47.82%) | |
| Age (years) | 45±10.88 | 44.69±11.58 | 0.949 |
| Tumor size | 0.104 | ||
| Microadenoma | 10 (43.48%) | 9 (39.13%) | |
| Macroadenoma | 0 (0%) | 4 (17.39%) | |
| Invasiveness | 0.339 | ||
| Yes | 1 (4.35%) | 4 (17.39%) | |
| No | 9 (39.13%) | 9 (39.13%) | |
| Midnight serum cortisol (µg/24 h) | 21.08±5.81 | 20.74±8.08 | 0.912 |
| Urinary free cortisol (µg/24 h) | 524.09±239.90 | 710.53±369.07 | 0.181 |
| Plasma ACTH (pg/ml) | 148.01±173.53 | 309.79±508.49 | 0.348 |
SFRP2, secreted frizzled-related protein 2; ATCH, adrenocorticotro-phic hormone.